Researchers have engineered a 19-amino-acid peptide derived from inducible co-stimulator ligand that selectively inhibits activated alpha-v-beta-3 integrin on kidney podocytes, reducing protein in the urine across several animal models of acute and chronic kidney injury.
The work was done entirely in cultured cells and rodents, and the authors describe it as proof of concept with dose-response, administration routes and larger cohorts all still to be established. The target is worth explaining: podocytes are the cells that anchor the kidney's filtration barrier, and overactivated alpha-v-beta-3 integrin is a recognized hallmark of renal inflammation in conditions including focal segmental glomerulosclerosis and diabetic nephropathy. No approved drug directly inhibits that receptor in kidney tissue.
Why previous integrin drugs failed
This is not a new idea, which is most of what makes the paper interesting. Monoclonal antibodies against integrins carry a risk of neutralizing immune responses over long-term dosing, and small-molecule inhibitors have struggled with off-target binding.
The cautionary example is cilengitide, a cyclic pentapeptide that flipped from antagonist at high concentrations to integrin agonist at lower ones during clinical trials. Those paradoxical effects contributed to failures in oncology and stalled translation in nephrology entirely.
The design trick
ICOSL is normally an immune co-stimulatory molecule, but the team isolated its integrin-binding RGD motif from the surface that engages the ICOS receptor, excluding the key contact residues that drive T-cell activation. The resulting peptide, hICOSL-19, bound human alpha-v-beta-3 integrin with a dissociation constant of 25.4 nanomolar and mouse integrin at 44.9 nanomolar, while a scrambled control peptide showed no measurable interaction.
Unmodified, it cleared fast: a terminal plasma half-life of 14.96 minutes. Adding twelve polyethylene glycol units extended that more than three-fold, to 46.74 minutes, without losing target affinity.
Key results
In BTBR ob/ob mice, a genetic model of obesity and advanced diabetic nephropathy, daily intravenous dosing at 500 micrograms per kilogram for six weeks significantly reduced the urinary albumin-to-creatinine ratio against animals given an inactive control peptide, with no change in body weight. Electron microscopy showed less podocyte foot process effacement and normalization of basement membrane thickening.
Limitations
Only one dose was tested, and the diabetic cohort was small. Human trials have not begun, and the authors note that nephrology runs on combination regimens, so interactions with RAAS inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists remain unexamined.
Bottom line
A clean safety signal and consistent results across mechanical, metabolic and immunological injury models is a stronger preclinical package than most peptide stories arrive with. It is still rodent data on a target that has defeated three previous drug classes.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.